A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Community Cancer Institute
Clovis, California, United States
- Memorial Health University Medical Center
Savannah, Georgia, United States
- Women'S Cancer Care
Covington, Louisiana, United States
- Stephenson Cancer Center
Oklahoma City, Oklahoma, United States
- University of Vermont Medical Center
Burlington, Vermont, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 23 Aug 2019
- Primary completion
- 24 Aug 2020
- Completion
- 24 Aug 2020
- Last update posted
- 12 Jun 2023
- Registered enrollment
- 1
- Registry id
- NCT03824704
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.